Literatur
- 1
Dormandy J A, Charbonnel B, Eckland D J. et al .
Secondary prevention of macrovascular events in patients with type 2 diabetes in the
PROactive Study.
Lancet.
2005;
366
(9493)
1279-1289
- 2
Eckert S, Erdmann E, Lundershausen R. et al .
Konsensuspapier Pioglitazon in DMW.
DMW.
2007;
132
2650-2653
- 3
Gaede P, Vedel P, Larsen N. et al .
Multifactorial intervention and cardiovscular disease in patients with type 2 diabetes.
N Engl J Med.
2003;
348
383-93
- 4
Jackisch-Riemann A, Püntmann I, Mühlbauer B.
Pioglitazon und die PROactive-Studie. Weniger Antworten als Fragen.
Bremer Ärztejournal.
2005;
12
14
- 5
Nathan D M.
Finding new treatments for diabetes - how many, how fast, how good?.
N Engl J Med.
2007;
356
437-440
- 6
Rottlaender D, Michels G, Erdmann E. et al .
Therapie mit Glitazonen.
DMW.
2007;
132
2629-2632
- 7
Sigal R, Malcolm J, Arnaut A.
Prevention of cardiovascular events in diabetes.
BMJ Clinical Evidence.
2006;
02
601
- 8
Yki Yärvinnen H.
The PROactive Study:some answers, many questions.
Lancet.
2005;
366
1241-1242
Dr. med. U. F. Gundel
Römersteinstr. 4
72766 Reutlingen
Phone: 07121/491246
Fax: 07121/470529
Email: info@dr-gundel.de
